Oppenheimer Maintains Outperform on Soleno Therapeutics, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Soleno Therapeutics (NASDAQ:SLNO) and raises the price target from $8 to $14.
September 15, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst has maintained an Outperform rating on Soleno Therapeutics and raised the price target from $8 to $14.
The raised price target by Oppenheimer indicates a positive outlook for Soleno Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100